According to news reports, The Very Group, is looking to float after calling off their plan for a £4bn IPO last year due to a volatile market. The ecommerce group is owned by the Barclays family. According to the Sunday Times, the retailer has offered incentives to senior leaders at the firm for pulling off a flotation, which the Barclays family now hope to get underway in mid-2023.
Psych Capital PLC, intends to list on the AQSE Growth Market. Psych operates the Psych Platform (a business-to-business networking platform), that is developing the Blossom Database pursuant to a third party licensing arrangement. The Company also has an investment of 426,000 common shares in Awakn, a Canadian NEO Exchange listed psychedelics research and clinical group, with operations in the UK and Europe. Psych is developing the Blossom Database pursuant to a third-party licensing arrangement, and Psych will work to develop an artificial intelligence platform that will provide biotech companies advanced clinical data that will be able to fast-track drug development and loop back the real-world data, in a centralised database, to provide feedback on molecules and associated therapy programmes. Due Date 9th June 2022.
Altona Rare Earths, the AQSE listed mining exploration Company focused on the evaluation, acquisition and development of Rare Earth Elements mining projects in Africa, intends to join the Main Market. Admission to trading of the Company’s Ordinary Shares on the AQSE Growth Market will be cancelled simultaneously with Admission. It is also proposed that on Admission, the Company will change its EPIC from AQSE:ANR to REE. The Company also seeks to raise funds to finance its current and future rare earths mining projects in Southern and Eastern Africa. Due June 2022.
Atlantic Lithium 52.8p £305.2m (ALL.L)
The funded, African- focussed lithium exploration and development company on track to bring West Africa’s first lithium mine into production, announced the mobilisation of an additional 3 drill rigs, the expansion of the drilling programme and new drilling observations at the Ewoyaa Lithium Project in Ghana, West Africa where it has defined a JORC (2012) compliant Mineral Resource Estimate (MRE) of 30.1Mt @1.26% Li2O. Approximately 9,166m of reverse circulation (RC) drilling for 52 holes completed to date with assays pending. Multiple and significant visual spodumene pegmatite drill intercepts observed up to 80m long in RC drill chips; assays pending. Second and third RC drill rigs arrived on site and commenced drilling; a diamond core drilling rig is due to arrive on site next week, increasing the total number of drilling rigs on site to four. The Company’s intention to deliver a Pre-Feasibility Study (PFS) during Q3 2022 remains unchanged despite delays in receiving assay results from labs experiencing heightened demand.
Bens Creek 84.5p £299.5m (BEN.L)
The owner of a metallurgical coal mine in North America supplying the steel industry, confirms that the Company has commenced underground mining for the production of High Vol A (HVA) coal. The current price (on 24 May 2022) was $468 per metric tonne. Adam Wilson, Chief Executive Officer of Bens Creek, commented: “We are delighted that our auditors, PKF Littlejohn, and our nominated adviser, Allenby Capital Limited, were in attendance this week with the management team of Bens Creek to see the commencement of underground mining for our HVA product. This product enhances our offering to Integrity Coal Sales Inc., our offtake partner. The addition of HVA to our product line will further add value to our business.”
Beowulf Mining 5.45p £45.3m (BEM.L)
The mineral exploration and development company, informs that its CEO, Kurt Budge, has provided an update in an interview with BRR Media following the publication of the Company’s Audited Financial Results for the year ended 31 December 2021. During the interview Kurt Budge discusses: The Company’s progress in 2021; Developments with Grafintec in Finland; The award of the Kallak North Exploitation Concession; and The Company’s focus on stakeholder engagement, including the need for an Informed Consultation and Participation process. The interview can be viewed following the link below: https://www.brrmedia.co.uk/broadcasts-embed/628ba917fa4eb04c1a54f523/beowulf-full-year-results/?popup=true
CAP-XX 4.3p £21.9m (CPX.L)
CAP-XX Limited, a world leader in the design and manufacture of thin, flat supercapacitors and energy management systems, announced that following its collaboration with the University of New South Wales (UNSW, or the University), Sydney, it has today posted on its web site https://www.cap-xx.com/corporate-videos/ a short video produced by the University outlining its collaborative work with CAP-XX on the optimisation of supercapacitor performance. CAP-XX has been working with UNSW since 2017, when the University set up a series of sophisticated experiments to improve the leakage, current and lifetime performance in cells, under the leadership of Professor Neeraj. Professor Neeraj used the advanced capabilities available at UNSW to analyse the cell performance of CAP-XX’s supercapacitors at the microscopic and molecular level. As a direct result of a tailored programme of research started in 2019, Professor Neeraj has enabled CAP-XX’s R&D team to improve its understanding of the various mechanisms occurring within the cells. This has resulted in new IP, which has a direct commercial application in the development of CAP-XX’s new 3 volt (3V) product which incorporates this IP. The result is a supercapacitor with exceptionally low leakage current. Low leakage current is arguably the single most important parameter when considering a 3V supercapacitor being directly connected to a battery, especially a non-rechargeable battery. The Company is currently in preparation for the launch of the new 3V supercapacitor at the end of 2022, which will utilise the former Murata production lines now installed at the Company’s Seven Hills facility in Sydney, Australia. The Company had planned to do this work at its Malaysian manufacturing site but continual delays caused by COVID and the results from UNSW prompted the Company to pivot back to using the Sydney site. The 3V supercapacitor, when launched, will provide a high-performance complement to traditional 3 volt coin cell batteries.
Curtis Banks 266p £117.9m (CBP.L)
One of the UK’s leading SIPP providers, announces that the Company’s AGM will be held today. The Company also announces that immediately following the AGM, Chris Macdonald (Chairman) and Jules Hydleman (Non-Executive Director) will retire from the Board having served in their respective positions since 2015, shortly before the Company’s listing on AIM. Following Chris and Jules’ retirement from the Board, David Barral will be appointed independent Chairman with Christopher Mills appointed Non-Executive Director. David brings a wealth of experience to the Curtis Banks Group following an extensive executive and Non-Executive career in financial services spanning 40 years. His current portfolio includes Non-Executive director Chair of Rowanmoor Group and Non-Executive director of The Pensions Superfund. David brings a mix of strategic leadership, transformation and operational experience with a strong focus on value creation, performance, customers and risk and governance. Christopher is Chief Executive Officer and principal shareholder of Harwood Capital Management since 2011. He founded JO Hambro Capital Management with Jamie Hambro in 1993, acting as Chief Investment Officer, and Harwood Wealth with Alan Durant in 2013 until their respective sales in 2011 and 2020. He is CEO of North Atlantic Smaller Companies Investment Trust which he has managed since 1982 and Executive Director of Oryx International Growth Fund which he has managed since 1995. He has sat on the Board of over 100 companies during his career including most recently Augean, MJ Gleeson, SureServe, Frenkel Topping and is currently Chairman of EKF Diagnostics and Renalytix AI. He was awarded a scholarship to go to university by Samuel Montagu and has a BA in Business Studies.
Intuitive Investments 13.5p £9.9m (IIG.L)
Update in respect of its largest single investment, Sanondaf. Sanondaf, a specialist disinfection and hygiene services business, has awarded a regional franchise in Kent, which covers the Discovery Science Park in Sandwich. The franchise will be headed by John Wamsley who runs a successful equipment supply and reconditioning business. He has an extensive knowledge of, and excellent relationships in, the life sciences sector. This new regional franchise increases the number of regional franchises to 26, giving excellent and growing coverage throughout the United Kingdom. The award is in line with Sanondaf’s targeted growth strategy in the life science sector. Sanondaf is a trusted partner of companies ranging from life science start-ups to multi-nationals. Customers include the NHS, research laboratories and pharmaceutical manufacturers. Furthermore, Sanondaf announces three appointments. Tom Hyland, Operations Director, has held senior positions in global life sciences companies including Johnson & Johnson Medical, Microsulis, Life Technologies and Alere Technologies. Tom started his career as a chemical engineer, has a chemistry degree and holds an MBA. Tom combines excellent technical engineering ability with exceptional managerial skills and will be responsible for operations and product development. Collette McMorrow, Business Manager, has proven expertise in marketing, project management, business development and event management. Collette has held senior roles in leading companies such as Bayer and has a proven track record in digital system design, leadership, and performance management. Helen McPike, Product Specialist, is a biosecurity specialist who has 20 years’ experience in healthcare and has spent the last eight years working in the infection prevention and control sector. Helen has held senior sales roles and worked for the NHS, Byotrol and Fresnius and has first class honours science degree in Health Science.
Poolbeg Pharma 8.1p £40.5m (POLB.L)
The clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections. The USPTO granted a patent for the majority of Poolbeg’s claims around the use of certain p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment or prevention of severe influenza and the hypercytokinaemia (or cytokine storm) it causes through modulation of the immune response (reducing the body’s hyperinflammatory response to the virus). The USPTO granted a patent for the identification of defective interfering (DI) RNA-based influenza viruses for use against infection by influenza, that provides a drug candidate with both antiviral prophylactic and therapeutic applications. By having a dual mechanism of action POLB 002 (which was identified using this method) directly interferes with influenza virus replication blocking disease progression and also triggers nasal cells into an antiviral state. In this way, POLB 002 could provide pan-viral protection from respiratory virus infections including influenza, respiratory syncytial virus, SARS-CoV-2 and others
Strix Group 185.9p £385.6m (KETL.L)
The global leader in the design, manufacture and supply of kettle safety controls and other complementary water temperature management components provides an update ahead of its AGM today. At the meeting, Mark Bartlett, Chief Executive Officer of Strix, will make the following statement: “We confirm that based on year to date performance, our current expectations of trading conditions in the balance of the year, the resilience of our historical H2 performance through prior macroeconomic cycles and our experience during the COVID-19 pandemic, we are maintaining expectations for the full year. Since the announcement of our full year results, the global outlook has weakened and headwinds persist which imply that we will continue to face a challenging operating environment. However, we are pleased to have successfully implemented further product price increases across our full kettle controls range and water categories (the most recent was with effect from 1st May). This alongside a range of continued strategic efficiency measures, including the adoption of lean and automated processes at the new manufacturing operations, foreign exchange rate and commodity hedging arrangements has continued to minimise the impact of ongoing cost inflation. We continue to monitor the evolving situation in China and, to date, our manufacturing operations within Zengcheng district in Guangzhou have not been materially affected. We continue to take a proactive approach to minimise potential supply chain disruption by increasing levels of finished stock and holding stock in multiple districts. Overall, Strix has a robust business model, remains in a strong financial position and through adopting a disciplined and dynamic approach to our strategy has delivered a resilient performance during prior macroeconomic cycles and during the COVID-19 pandemic. We remain confident in our ability to navigate current uncertainties and deliver on the current expectations for the full year and against our medium-term targets.”
Yü Group 195p £32.3m (YU..L)
AGM trading update from the independent supplier of gas, electricity and water to the UK corporate sector. The Group reported a strong start to the year with the good momentum from FY2021 continuing and expects the overall Company performance in FY2022 to be in line with market expectations. The four months ending 30 April 2022 has seen significant revenue growth, at improved profit margins, compared to the same period in 2021. This provides management with high confidence for the remainder of FY2022. Average monthly bookings for the four months to 30 April 2022 stood at £13.0m, up 81% compared to the same period in 2021.The Group remains focused on delivering profitable and controlled growth, based on a strong forward contract book as well as unlocking the benefits of its ‘Digital by Default’ strategy. During the period the Group also announced the creation of a Metering Services Division providing the ability to control a larger part of the value chain and drive significant value enhancement over the medium term. Yü Group will provide a further update in its July trading update, covering the period to 30 June 2022.
Zinc Media Group 116p £18.8m (ZIN.L)
The TV and multimedia content producer, announced a trading update ahead of its AGM for the year ending 31 December 2021 being held today. In the last four weeks since its last update on 22 April, the Company has won an additional £4m of new business which will be booked across 2022 as these commissions enter production. As a result, in the year to date, revenue already booked into 2022 is at £17m. This compares to reported Group revenue for the full year ended 31 December 2021 of £17.5m. The Group’s pipeline remains strong for 2022 with £7m in highly advanced discussions. This latest new business includes several series recommissions from the Group’s popular factual label Red Sauce and from Nation’s producer Tern TV.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
